Canterbury DHB



A treatment plan can only be made after establishing the correct diagnosis and assessing end organ damage. The most common mutation and target for treatment in MPN is FIP1L1/PPDGFR, which is the target for imatinib and other TKIs.

Imatinib 100 mg daily is considered first-line therapy. As of July 2018, it is not known whether therapy is required in all patients with this mutation, or only those with evidence of organ damage.

Manage reactive eosinophilia by treating the underlying condition. If the underlying condition is not amenable to treatment, the eosinophilia itself can often be managed with corticosteroids or hydroxyurea.

About this Canterbury DHB document (6249):

Document Owner:

Bridgett McDiarmid (see Who's Who)

Last Reviewed:

August 2018

Next Review:

April 2021


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 6249